Deal strengthens Perrigo’s over-the-counter portfolio and pushes strongly into Europe

Consumer healthcare heavyweight Perrigo has agreed to buy Belgian over-the-counter specialist Omega Pharma for €3.6 billion (£2.8 billion), including €1.1 billion in assumed debt.

The former US-based Perrigo, which reincorporated in Ireland for tax reasons after buying Elan in 2013, will make use of Omega’s established distribution networks in Europe to further expand its geographic reach, and exercise its own networks to market Omega’s over-the-counter drugs portfolio more widely.